Shandong Sito Bio-technology Co Ltd - Asset Resilience Ratio
Shandong Sito Bio-technology Co Ltd (300583) has an Asset Resilience Ratio of 0.35% as of September 2020. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Also explore Shandong Sito Bio-technology Co Ltd assets under control for the complete picture of this company's asset base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2019)
This chart shows how Shandong Sito Bio-technology Co Ltd's Asset Resilience Ratio has changed over time. See 300583 equity financing ratio to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Shandong Sito Bio-technology Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Shandong Sito Bio-technology Co Ltd.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥10.00 Million | 0.35% |
| Total Liquid Assets | CN¥10.00 Million | 0.35% |
Asset Resilience Insights
- Limited Liquidity: Shandong Sito Bio-technology Co Ltd maintains only 0.35% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Shandong Sito Bio-technology Co Ltd Industry Peers by Asset Resilience Ratio
Compare Shandong Sito Bio-technology Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Royalty Pharma Plc
NASDAQ:RPRX |
Biotechnology | 0.11% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 65.12% |
|
Hyundai Bioscience Co. Ltd
KQ:048410 |
Biotechnology | 13.57% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 82.25% |
|
Lifecome Biochemistry Co Ltd
SHE:002868 |
Biotechnology | 4.69% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
Annual Asset Resilience Ratio for Shandong Sito Bio-technology Co Ltd (2017–2019)
The table below shows the annual Asset Resilience Ratio data for Shandong Sito Bio-technology Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2019-12-31 | 6.81% | CN¥203.36 Million ≈ $29.76 Million |
CN¥2.99 Billion ≈ $437.13 Million |
-14.84pp |
| 2018-12-31 | 21.64% | CN¥561.57 Million ≈ $82.18 Million |
CN¥2.59 Billion ≈ $379.65 Million |
-5.96pp |
| 2017-12-31 | 27.61% | CN¥558.88 Million ≈ $81.78 Million |
CN¥2.02 Billion ≈ $296.26 Million |
-- |
About Shandong Sito Bio-technology Co Ltd
Shandong Sito Bio-technology Co., Ltd. researches, develops, and produces steroid biomedicine intermediates. Its products include 9a-hydroxyandrost, 17a-hydroxyprogesterone, 17a-hydroxy progesterone derivatives, anecort acetate, neomycin sulfate, progesterone intermediate, tylvalosin tartrate, tetraene acetate, androstenedione, bisnoralcohol, norandrostenedione, ethylene deltenone, 16ß and 16a me… Read more